R&D channel feed

Bound­less shares dip as it nix­es can­cer as­set, reshuf­fles ex­ecs

5 months ago
People

BeiGene li­cens­es sol­id tu­mor drug, match­es with Ideaya’s com­bo plans

5 months ago
Deals

CDK4 in­hibitors from BeiGene and Pfiz­er, ALX’s CD47 drug take the stage at SABCS

5 months ago
Pharma

Re­pare plans for Phase 3 en­dome­tri­al can­cer study, sidelin­ing ovar­i­an can­cer

5 months ago

Af­ter poor lung can­cer da­ta, iTeos drops in­u­padenant to dou­ble down on TIG­IT

5 months ago

Ed­i­tas to cut 65% of work­force, of­fi­cial­ly stops work on ex vi­vo sick­le cell ther­a­py

5 months ago
Cell/Gene Tx

Safe­ty con­cerns and tri­al holds for pe­di­atric RSV vac­cines prompt cau­tion from FDA ad­comm

5 months ago
Pharma
FDA+

Pfiz­er shares pos­i­tive Phase 3 re­sults in breast can­cer sub­set 

5 months ago

Keros halts parts of Phase 2 PAH tri­al due to safe­ty, stock tanks 70%

5 months ago

Cor­cept’s ALS drug fails to im­prove func­tion in Phase 2 study

5 months ago

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

5 months ago
Pharma

NIH halts en­roll­ment in tri­al for SIGA's mpox an­tivi­ral af­ter dis­ap­point­ing da­ta

5 months ago

Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects

5 months ago
Pharma

Re­lay Ther­a­peu­tics plans piv­otal tri­al in sec­ond-line breast can­cer for 2025

5 months ago

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

5 months ago

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

5 months ago

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

5 months ago

Q32 Bio’s stock crash­es af­ter atopic der­mati­tis fail, alope­cia tri­al sna­fu

5 months ago

The End­points 100: The biotech in­dus­try braces for Trump 2.0

5 months ago
Deals
Bioregnum

Bay­er ex­its Eu­rope pact with Moberg for nail fun­gus drug af­ter Phase 3 fail

5 months ago
Deals

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

5 months ago

NewAms­ter­dam hits pri­ma­ry end­point in lat­est Phase 3 tri­al of CETP in­hibitor

5 months ago
Pharma

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

5 months ago
FDA+

Cardiff un­veils pos­i­tive Phase 2 da­ta for col­orec­tal can­cer drug, $40M of­fer­ing

5 months ago
First page Previous page 12131415161718 Next page Last page
A service from the Financial Times